Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -33.06% is in line with its 5-year average of -34.98%, around the middle of its 5-year range (-88.70%–9.02%).
As of the fiscal period ended Tuesday, June 30, 2026. 189.97% below its 12-month average of -11.40%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -33.06%.
RETURN ON EQUITY (ROE)
-33.06%
RETURN ON EQUITY (ROE) AVG TTM
-11.40%
RETURN ON EQUITY (ROE) AVG 3Y
-38.34%
RETURN ON EQUITY (ROE) AVG 5Y
-34.98%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-189.97%
CURRENT VS 3Y AVG
+13.76%
CURRENT VS 5Y AVG
+5.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
+17.75%
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$858.31M
Return on Equity (ROE)
-33.06%
TTM Avg
-11.40%
3Y Avg
-38.34%
5Y Avg
-34.98%
Market Cap
$847.61M
Return on Equity (ROE)
-59.07%
TTM Avg
-63.84%
3Y Avg
-29.19%
5Y Avg
-3.25%
Market Cap
$846.26M
Return on Equity (ROE)
-28.46%
TTM Avg
-48.75%
3Y Avg
-33.66%
5Y Avg
-33.66%
Market Cap
$838.75M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
Market Cap
$877.41M
Return on Equity (ROE)
75.67%
TTM Avg
312.76%
3Y Avg
285.83%
5Y Avg
166.15%
Market Cap
$831.91M
Return on Equity (ROE)
-34.83%
TTM Avg
-64.71%
3Y Avg
-59.77%
5Y Avg
-96.53%
Market Cap
$888.21M
Return on Equity (ROE)
-24.02%
TTM Avg
-108.12%
3Y Avg
-89.93%
5Y Avg
-68.76%
Market Cap
$898.61M
Return on Equity (ROE)
23.86%
TTM Avg
-5.16%
3Y Avg
-37.28%
5Y Avg
-22.23%
Market Cap
$819.99M
Return on Equity (ROE)
N/A
TTM Avg
-5137.85%
3Y Avg
-2593.82%
5Y Avg
-1731.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $858.31M | -33.06% | -11.40% | -38.34% | -34.98% |
| QuidelOrtho Corporation (QDEL)vs › | $847.61M | -59.07% | -63.84% | -29.19% | -3.25% |
| Beta Bionics, Inc. (BBNX)vs › | $846.26M | -28.46% | -48.75% | -33.66% | -33.66% |
| Alumis Inc. (ALMS)vs › | $838.75M | -97.08% | -96.94% | -22.72% | -22.72% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $877.41M | 75.67% | 312.76% | 285.83% | 166.15% |
| Jade Biosciences, Inc. (JBIO)vs › | $831.91M | -34.83% | -64.71% | -59.77% | -96.53% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $888.21M | -24.02% | -108.12% | -89.93% | -68.76% |
| Bioventus Inc. (BVS)vs › | $898.61M | 23.86% | -5.16% | -37.28% | -22.23% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $819.99M | N/A | -5137.85% | -2593.82% | -1731.57% |
| Arbutus Biopharma Corp (ABUS)vs › | $900.79M | 59.16% | -57.78% | -58.75% | -57.09% |
ROE
-33.1%
ROA
-23.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -33.06% |
| 2026-03-31 | -24.91% |
| 2025-12-31 | -16.57% |
| 2025-09-30 | 8.52% |
| 2025-06-30 | 9.02% |
| 2025-03-31 | 2.24% |
| 2024-12-31 | -32.61% |
| 2024-09-30 | -58.11% |
| 2024-06-30 | -58.05% |
| 2024-03-31 | -88.70% |
| 2023-12-31 | -75.51% |
| 2023-09-30 | -72.01% |
| 2023-06-30 | -58.65% |
| 2023-03-31 | -47.84% |
| 2022-12-31 | -39.98% |
| 2022-09-30 | -34.75% |
| 2022-06-30 | -31.01% |
| 2022-03-31 | -26.27% |
| 2021-12-31 | -21.28% |
| 2021-09-30 | -19.00% |
| 2021-06-30 | -15.95% |
